Medication options are available to help manage the cognitive and behavioral symptoms of dementia and Alzheimer's disease.

Differences in outcomes between patients with early Alzheimer’s disease who used lecanemab and matched controls increased ...

Four years of lecanemab treatment led to less cognitive decline and potentially even improvement in clinical scores over time, with a favorable safety profile, in the open-label extension trial.

TORONTO -- An investigational subcutaneous autoinjector showed comparable efficacy and safety to the IV formulation of lecanemab (Leqembi) for maintenance treatment in early Alzheimer's disease, ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, ...

The females in my family on my mother's side seem to develop dementia/Alzheimer's on a fairly regular basis. It seems to ...

Advanced imaging, such as PET scans, are beginning to show the ability to diagnose Alzheimer’s dementia in people with early ...

Long-term treatment with lecanemab shows slowed progression of early Alzheimer’s disease, according to data presented at the ...

From taking HRT to eating a healthy diet, Kate Muir shares some of the precautionary measures she's trying to avoid ...

A health ministry panel Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese ...

Biogen and Eisai’s Alzheimer’s disease (AD) drug Leqembi (lecanemab) has shown continued benefit over four years, according ...

BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai presented the latest findings on lecanemab (Leqembi®) at the Alzheimer's Association International Conference (AAIC), held in Toronto, ...